MedTrace Logo

Haloperidol for the Treatment of Nausea and Vomiting in the ED

NCT04764344 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-06-01

No results posted yet for this study

Summary

Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of nausea or vomiting. A total of 300 patients age 18-55 presenting to the emergency department with chief complaint of nausea or vomiting will be enrolled from February 2021 - February 2022. Patients will be randomized and symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by telephone at 24 hours.

Conditions

Interventions

DRUG

Haloperidol

2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP

DRUG

Ondansetron

Ondansetron

Sponsors & Collaborators

  • Western Michigan University School of Medicine

    lead OTHER

Principal Investigators

  • Jessica McCoy, MD · Western Michigan University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2023-05-22
Completion
2023-05-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04764344 on ClinicalTrials.gov